Search Results - "Vreman, R"

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen by van Nuland, M., Vreman, R. A., ten Ham, R. M. T., de Vries Schultink, A. H. M., Rosing, H., Schellens, J. H. M., Beijnen, J. H., Hövels, A. M.

“…Purpose Breast cancer is the most common malignancy in women worldwide. Recurrence rates in breast cancer are considered to be dependent on the serum…”
Get full text

PNS6 Developing a Conceptual Framework to Guide the Innovation of Methods for Health Technology Assessment by Jiu, L., Vreman, R., Mantel-Teeuwisse, A.K., Goettsch, W.

Get full text

PNS167 Challenges in Health Technology Assessment of Complex Health Technologies by Hogervorst, M., Vreman, R., Mantel-Teeuwisse, A.K., Goettsch, W.

Get full text

Oral Presentation: Adverse Events to COVID-19 Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries by Ogar, C, Quick, J, Gilbert, H N, Vreman, R A, Teeuwisse, A K M, Mugunga, J C

“…Introduction: As of April 3, 2022, 31 COVID-19 vaccines had received approval for use globally (1). With the fast-tracked development and concurrent…”
Get full text

Cost-effectiveness of clopidogrel versus ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome by Van Den Broek, W W A, Van Paassen, J G, Gimbel, M E, Deneer, V H M, Ten Berg, J M, Vreman, R A

Get full text

PMU102 DIFFERENCES IN HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONS BETWEEN EUROPEAN JURISDICTIONS: THE ROLE OF PRACTICE VARIATIONS by Vreman, R., Mantel-Teeuwisse, A.K., Hovels, A.M., Leufkens, H.G., Goettsch, W.

Get full text

PRM145 - A NEW GRAPHICAL REPRESENTATION OF PROBABILITY SENSITIVITY ANALYSIS RESULTS AS AN ALTERNATIVE FOR THE SCATTER-PLOT by Geenen, JW, Vreman, R, ten Ham, R.M., Boersma, C, Klungel, O, Hovels, A.M.

Get full text

PSY176 - SIGNIFICANT BENEFIT AND RELATIVE EFFECTIVENESS ASSESSMENT OF ORPHAN MEDICINAL PRODUCTS IN THE EUROPEAN UNION: A COMPARATIVE ANALYSIS by de Ruijter, A., Sidiropoulos, I., Larsson, K., Vreman, R., Berntgen, M., Goettsch, W.

Get full text

PCN191 - COST-EFFECTIVENESS OF MONITORING ENDOXIFEN LEVELS IN BREAST CANCER PATIENTS ADJUVANTLY TREATED WITH TAMOXIFEN by Vreman, R., van Nuland, M., ten Ham, R.M., de Vries-Schultink, A.H., Rosing, H., Schellens, J.H., Beijnen, J.H., Hovels, A.M.

Get full text

D107 TUBERCULOSIS INFECTION AND DISEASE: EPIDEMIOLOGY AND DIAGNOSIS: Prospects For Elimination: An Individual-Based Model To Assess Tb Control Strategies In California by Goodell, A J, Shete, P B, Vreman, R, Metcalfe, J, Porco, T C, Barry, P M, Flood, J, Marks, S, Cattamanchi, A, Kahn, J G

Get full text

S14 THE HEALTH AND BEHAVIOURAL CONSEQUENCES OF ALCOHOL HANGOVER by Owen, L., Heffernan, T., Bervoets, A. C., de Klerk, S., Vreman, R. A., Olivier, B., Brookhuis, K. A., Roth, T., Verster, J. C., van Doornen, L. J. P., Kleinjan, M., Garssen, J., de Haan, L., Penning, R., Slot, K. A.

Get full text

HPR184 Uncertainties Around Tumour Agnostic Therapies in Europe: Barriers and Facilitators of Patient Access by Hogervorst, M, Goettsch, W, Mantel-Teeuwisse, AK, Bloem, L, Vreman, RA

Get full text

HPR156 Payment and Reimbursement Models for Innovative High-Priced Hospital Drugs in the Netherlands: A Survey of Stakeholder's Attitudes and Experiences by Callenbach, MHE, Vreman, RA, Goettsch, WG, Mantel-Teeuwisse, AK

Get full text

POSC311 The Methodological Quality of Retrospective Observational Studies to Evaluate Glucose Monitoring Systems in Diabetes Patients: A Systematic Review by Jiu, L, Junfeng, W, Vreman, RA, Mantel-Teeuwisse, AK, Goettsch, W

Get full text

HTA45 Uncertainty Regarding the Long-Term Effectiveness of New Therapies in Health Technology Assessment by Versteeg, JW, Hogervorst, M, Mantel-Teeuwisse, AK, Goettsch, WG, Vreman, RA

Get full text

HPR10 Building Bridges Between Regulation, Health Technology Assessment and Clinical Guideline Development by Hogervorst, M, Mollebaek, M, Vreman, RA, Wang, J, Mantel-Teeuwisse, AK, Goettsch, W

Get full text

OP18 Applicability of Appraisal Tools of Real-World Evidence in Health Technology Assessment: A Literature Review and Content Analysis by Jiu, L, Hartog, MK, Wang, J, Vreman, RA, Mantel-Teeuwisse, AK, Goettsch, WG

Get full text

The Introduction Of A Threshold For The Icer And The Implications For Reimbursement Of Drugs In The Dutch Healthcare System by Karpenko, AW, Geenen, JW, Vreman, RA, Hovels, A

“…OBJECTIVES: The National Health Care Institute (ZIN) advises the minister of healthcare (MOH) if a drug should be reimbursed. Recently it was suggested to…”
Get full text

PHP111 - The Introduction Of A Threshold For The Icer And The Implications For Reimbursement Of Drugs In The Dutch Healthcare System by Karpenko, AW, Geenen, JW, Vreman, RA, Hovels, A

Get full text

Predicting Budget Impact: A Mixed-Effects Model Approach by Geenen, JW, Belitser, SV, Vreman, RA, Klungel, O, Raaijmakers, JA, Hovels, A

“…OBJECTIVES: In the past decade, many new oncology drugs entering the market have raised concerns on affordability. At market authorization (MA), data on budget…”
Get full text